ATPW
NBIX icon

Ashton Thomas Private Wealth’s Neurocrine Biosciences NBIX Stock Holding History

Ashton Thomas Private Wealth’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,541
Closed -$219K – 1537
2025
Q4 		$219K Buy
+1,541
New +$223K 0.01% 935
2024
Q3 		– Sell
-204
Closed -$28.1K – 1382
2024
Q2 		$28.1K Buy
+204
New +$28K ﹤0.01% 1065

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ashton Thomas Private Wealth's NBIX Position: Q1 2026 in Review

Ashton Thomas Private Wealth sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 1,541 shares — an estimated $219K sold.

Ashton Thomas Private Wealth first reported a position in NBIX in Q2 2024 and held it in 2 quarters. The position peaked at $219K in Q4 2025. 700 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Ashton Thomas Private Wealth reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
  • Ashton Thomas Private Wealth sold 1,541 Neurocrine Biosciences shares in Q1 2026, an estimated $219K.
  • Ashton Thomas Private Wealth first reported a position in Neurocrine Biosciences in Q2 2024 and held it in 2 quarters.
  • Ashton Thomas Private Wealth's Neurocrine Biosciences position peaked at $219K in Q4 2025.
  • 700 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Ashton Thomas Private Wealth's 13F filing for Q1 2026, filed 11 May 2026.